These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 22134754

  • 1. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [Abstract] [Full Text] [Related]

  • 2. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M.
    Int J Cancer; 2008 Mar 15; 122(6):1400-10. PubMed ID: 18027850
    [Abstract] [Full Text] [Related]

  • 3. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, Carducci M, Rodriguez R.
    Cancer Res; 2006 Jul 15; 66(14):7237-44. PubMed ID: 16849572
    [Abstract] [Full Text] [Related]

  • 4. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
    Kim J, Park H, Im JY, Choi WS, Kim HS.
    Anticancer Res; 2007 Jul 15; 27(5A):3285-92. PubMed ID: 17970072
    [Abstract] [Full Text] [Related]

  • 5. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS.
    Biomed Pharmacother; 2013 Jun 15; 67(5):407-15. PubMed ID: 23583193
    [Abstract] [Full Text] [Related]

  • 6. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug 15; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 7. ProstaCaid induces G2/M cell cycle arrest and apoptosis in human and mouse androgen-dependent and-independent prostate cancer cells.
    Yan J, Katz AE.
    Integr Cancer Ther; 2010 Jun 15; 9(2):186-96. PubMed ID: 20587444
    [Abstract] [Full Text] [Related]

  • 8. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
    Saleem M, Kweon MH, Yun JM, Adhami VM, Khan N, Syed DN, Mukhtar H.
    Cancer Res; 2005 Dec 01; 65(23):11203-13. PubMed ID: 16322271
    [Abstract] [Full Text] [Related]

  • 9. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K, Pašková L, Matiješčuková N, Kolář Z.
    Cancer Biomark; 2010 Dec 01; 7(2):79-90. PubMed ID: 21178266
    [Abstract] [Full Text] [Related]

  • 10. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 12. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL, Lin JK.
    Prostate; 2008 Jan 01; 68(1):61-71. PubMed ID: 18008333
    [Abstract] [Full Text] [Related]

  • 13. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.
    Anticancer Drugs; 2009 Sep 01; 20(8):682-92. PubMed ID: 19606018
    [Abstract] [Full Text] [Related]

  • 14. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
    Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP.
    Cancer Res; 2007 Feb 15; 67(4):1636-44. PubMed ID: 17308104
    [Abstract] [Full Text] [Related]

  • 15. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 16. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S.
    J Urol; 2012 Jul 15; 188(1):300-6. PubMed ID: 22608750
    [Abstract] [Full Text] [Related]

  • 17. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
    Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB.
    Cancer Res; 1995 Jul 15; 55(14):3197-203. PubMed ID: 7606741
    [Abstract] [Full Text] [Related]

  • 18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.
    Cancer Chemother Pharmacol; 2010 Nov 15; 66(6):1131-40. PubMed ID: 20838997
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.
    PLoS One; 2013 Nov 15; 8(3):e58267. PubMed ID: 23469273
    [Abstract] [Full Text] [Related]

  • 20. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
    Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC.
    Prostate; 2008 Feb 01; 68(2):210-22. PubMed ID: 18092350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.